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he checkpoint protein Chfr delays entry into mitosis,
in the presence of mitotic stress (Scolnick, D.M., and
 
T.D. Halazonetis. 2000. 
 
Nature
 
. 406:430–435). We
show here that Chfr is a ubiquitin ligase, both in vitro and
in vivo. When transfected into HEK293T cells, Myc–Chfr
promotes the formation of high molecular weight ubiquitin
conjugates. The ring ﬁnger domain in Chfr is required for
the ligase activity; this domain auto-ubiquitinates, and
mutations of conserved residues in this domain abolish
the ligase activity. Using 
 
Xenopus
 
 cell-free extracts, we
demonstrated that Chfr delays the entry into mitosis by
negatively regulating the activation of the Cdc2 kinase at the
G2–M transition. Speciﬁcally, the Chfr pathway prolongs the
T
 
phosphorylated state of tyrosine 15 in Cdc2. The Chfr-
mediated cell cycle delay requires ubiquitin-dependent
protein degradation, because inactivating mutations in
Chfr, interference with poly-ubiquitination, and inhibition
of proteasomes all abolish this delay in mitotic entry. The
direct target of the Chfr pathway is Polo-like kinase 1
(Plk1). Ubiquitination of Plk1 by Chfr delays the activation
of the Cdc25C phosphatase and the inactivation of the
Wee1 kinase, leading to a delay in Cdc2 activation. Thus,
the Chfr pathway represents a novel checkpoint pathway
that regulates the entry into mitosis by ubiquitin-dependent
proteolysis.
 
Introduction
 
Cell cycle progression is monitored by checkpoint mechanisms
to ensure the integrity of the genome and the fidelity of
sister chromatid separation (Elledge, 1996). A cell cycle
checkpoint that acts at prophase has been recently discovered
(Scolnick and Halazonetis, 2000). In normal human cell
lines, chromosome condensation is delayed in response to
drugs that disrupt microtubule structure, such as taxol and
nocodazole, suggesting a checkpoint that functions at the
G2 to M transition (Jha et al., 1994). Although the exact
defects sensed by this checkpoint mechanism have not been
characterized, centrosome separation, which is inhibited in
these cells, is a likely target of this checkpoint (Scolnick and
Halazonetis, 2000). A key component of the checkpoint is
the Chfr protein that delays chromosome condensation and
nuclear envelope breakdown in response to mitotic stress in-
duced by taxol or nocodazole. In four out of eight human
tumor cell lines examined, the Chfr gene is either mutated
or not expressed, and the Chfr checkpoint does not function.
Ectopic expression of Chfr in these cells restores the cell cy-
cle delay, indicating that Chfr is required for the checkpoint
control (Scolnick and Halazonetis, 2000). The Chfr protein
contains three separate domains, an NH
 
2
 
-terminal forkhead-
associated (FHA)* domain, a central ring finger (RF) do-
main, and a COOH-terminal cysteine-rich (CR) domain.
Based on mutagenesis analysis, both the FHA and CR do-
mains are required for the checkpoint function (Scolnick
and Halazonetis, 2000). The importance of the RF domain
in Chfr function is yet to be determined.
Progression from G2 to M is controlled by activation of
the mitosis-promoting factor (MPF), a complex of the
catalytic kinase subunit, Cdc2, and its positive regulatory
subunit, cyclin B (King et al., 1994). As cells enter
prophase, accumulation of mitotic cyclin B leads to formation
of the Cdc2–cyclin B complex, which is then transported into
the nucleus (Murray and Kirschner, 1989; Solomon et al.,
1990). However, MPF is held in an inactive state by the
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Wee1 and Myt1 kinases, which phosphorylate Cdc2 on ty-
rosine 15 and threonine 14 and inhibit MPF activity (Rus-
sell and Nurse, 1987; Draetta et al., 1988; Featherstone and
Russell, 1991; Kornbluth et al., 1994; Mueller et al., 1995).
Activation of the Cdc2 kinase and entry into prometaphase
do not occur until the dual-specific phosphatase Cdc25C
dephosphorylates Cdc2 (Russell and Nurse, 1986; Gautier
et al., 1991; Kumagai and Dunphy, 1991, 1992; Osmani et
al., 1991). Once activated, MPF triggers chromosome con-
densation, breakdown of the nuclear envelope, and forma-
tion of the mitotic spindle.
The activity of MPF is not only controlled by posttransla-
tional modifications, such as phosphorylation and de-phos-
phorylation, but also by a ubiquitin-dependent proteolysis
pathway (Fang et al., 1999). Cyclin B is degraded by such a
pathway at late anaphase, which inactivates the Cdc2 kinase
and allows cells to exit from mitosis.
Ubiquitin-dependent proteolysis involves cascade reac-
tions of several enzymes, including a ubiquitin-activating
enzyme (E1), a ubiquitin-conjugating enzyme (E2), and a
ubiquitin ligase (E3). In this series of enzymatic reactions,
the critical enzyme is the ubiquitin ligase that links E2 to
substrates and provides specificity for the ubiquitination
pathway (Hershko and Ciechanover, 1998). A group of
ubiquitin ligases contains the ring finger domain (Lorick
et al., 1999; Huang et al., 2000; Joazeiro and Weissman,
2000). The prototype of this group of E3s is the proto-
oncogene c-Cbl that targets receptor tyrosine kinases for
ubiquitination and degradation (Joazeiro et al., 1999).
The RF domain in c-Cbl directly interacts with E2, and
c-Cbl functions to bring the E2–ubiquitin (Ub) conjugate
adjacent to substrates (Yokouchi et al., 1999; Zheng et
al., 2000). In the absence of substrates, the RF domain by
itself has an auto-ubiquitination activity, a hallmark for
this group of ubiquitin ligases (Joazeiro et al., 1999; Yo-
kouchi et al., 1999).
There are at least two ubiquitin ligases involved in cell cy-
cle control (King et al., 1996). The Skp1/cullin/F-box
(SCF) ligase recognizes an inhibitor of cyclin-dependent ki-
nase, sic1, and controls the G1–S transition (Krek, 1998;
Willems et al., 1999). A second ubiquitin ligase, the
anaphase-promoting complex/cyclosome (APC), controls
both the separation of sister chromatids and the exit from
mitosis by ubiquitinating multiple substrates, such as
anaphase inhibitors and mitotic cyclin B (Fang et al., 1999).
SCF and APC each contains a ring finger subunit (Roc1 and
APC11, respectively). It has been shown that both Roc1 and
APC11 auto-ubiquitinate and therefore have intrinsic ubiq-
uitin ligase activity, although the recognition of substrates
requires additional subunits (Ohta et al., 1999; Seol et al.,
1999; Gmachl et al., 2000; Leverson et al., 2000). Further-
more, the RF domain in each protein is critical for ligase ac-
tivity, because point mutations in RF domains abolish the li-
gase activity.
The checkpoint protein Chfr also contains a ring finger
domain (Scolnick and Halazonetis, 2000), raising the possi-
bility that Chfr may function as a ubiquitin ligase. We show
here that, like Roc1 and APC11, Chfr auto-ubiquitinates
and has intrinsic ubiquitin ligase activity. The RF domain is
both necessary and sufficient for the auto-ubiquitination ac-
tivity in vitro. Chfr also acts as a ubiquitin ligase in vivo, and
Myc–Chfr immunopurified from HEK293T cells promotes
the formation of high molecular weight ubiquitin conju-
gates. We characterized the specificity of Chfr toward ubiq-
uitin-conjugating enzymes, and found that both Ubc4 and
Ubc5, but not UbcH7 and UbcH10, function with the Chfr
ligase. Furthermore, we developed a cell-free system to ana-
lyze the biological function of Chfr ligase. When added to
 
Xenopus
 
 extracts, recombinant Chfr delays the activation of
the Cdc2 kinase during the G2 to M transition; this delay is
caused by a prolonged inhibitory phosphorylation of tyro-
sine 15 on Cdc2. The ubiquitin-dependent degradation by
active Chfr ligase is required for the mitotic delay. The tar-
get of the Chfr ligase is the Polo-like kinase 1 (Plk1), and
ubiquitination and degradation of Plk1 delays mitotic entry.
Thus, Chfr represents a novel ubiquitin ligase involved in
cell cycle regulation, and our biochemical analysis of the
Chfr function in 
 
Xenopus
 
 extracts provides a molecular
mechanism for Chfr-mediated checkpoint control at the G2
to M transition.
Figure 1. Chfr is a ubiquitin ligase. (A) 
Myc–Chfr (lanes 2) and control vector 
(lanes 1) were transfected into HEK293T 
cells and immunoprecipitated by an anti-
Myc antibody. The immunoprecipitates 
were analyzed by Western blotting with 
an anti-Myc antibody (panel I) or with 
an anti-ubiquitin antibody (panel II). In 
addition, immunoprecipitates were 
incubated with radioactive ubiquitin in 
the presence of recombinant E1 and 
Ubc4 and assayed for ubiquitin ligase 
activity (panel III). The molecular weight 
markers for panels I–III are labeled on 
the left side of panel I. (B) Purified 
recombinant Chfr protein assayed by 
12% SDS-PAGE. (C) Recombinant Chfr, 
at indicated final concentrations, was 
incubated with radioactive ubiquitin in the presence of E1 and Ubc4. The kinetics of the formation of the Chfr–Ub conjugates was assayed by 
12% reducing SDS-PAGE. The arrows point to the wells of the stacking gel and the arrowheads indicate the junction between stacking and 
separation gels. 
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Results
 
Chfr is a ubiquitin ligase
 
To test whether Chfr is a ubiquitin ligase, we transfected a
Myc-tagged 
 
Chfr
 
 gene into HEK293T cells (Fig. 1 A, panel
I). Myc–Chfr was immunopurified by an anti-Myc antibody
and assayed by Western blotting with an anti-ubiquitin anti-
body. The Chfr immunoprecipitate, but not the immuno-
precipitate from control transfected cells, contained a ubiq-
uitinated protein(s) (Fig. 1 A, panel II). It remains to be
determined whether the ubiquitinated protein is Chfr itself
or another protein associated with Chfr. Although the ma-
jority of the Myc–Chfr protein did not comigrate with the
ubiquitinated species (Fig. 1 A, compare panels I and II), we
cannot exclude the possibility that only a minor portion of
Myc–Chfr was ubiquitinated, and this minor species es-
caped detection in panel I.
We next tested whether the Myc–Chfr immunoprecipi-
tate had a ubiquitin ligase activity. The Myc–Chfr immuno-
precipitate was incubated with radioactive ubiquitin in the
presence of a recombinant ubiquitin activating (E1) and
conjugating (Ubc4) enzyme (Fig. 1 A, panel III). The Chfr
immunoprecipitate efficiently promoted the formation of
high molecular weight ubiquitin conjugates that did not en-
ter the stacking gel. Thus, the Chfr immunoprecipitate had
ubiquitin ligase activity. Because it is possible that the Chfr
immunoprecipitate may have contained additional proteins,
we do not know from this experiment whether the ubiquitin
ligase activity was directly derived from the Chfr protein,
nor do we know the nature of the ubiquitinated products.
It has been shown recently that several ring finger–con-
taining ubiquitin ligases can auto-ubiquitinate (Joazeiro et
al., 1999; Joazeiro and Weissman, 2000). To determine
whether the Chfr protein has intrinsic ubiquitin ligase activ-
ity, we examined the ability of recombinant Chfr to auto-
ubiquitinate. The Chfr protein was expressed in Sf9 cells and
purified to homogeneity (Fig. 1 B). When the Chfr protein
was incubated with radioactive ubiquitin in the presence of
the recombinant E1 and Ubc4, ubiquitin conjugates were ef-
ficiently formed (Fig. 1 C). These conjugates were resistant
 
to reduction by DTT, suggesting that ubiquitin is conju-
gated through an isopeptide bond rather than a thioester
bond. The formation of these ubiquitin conjugates was de-
pendent on E1, Ubc4, and Chfr; omitting any one of these
proteins resulted in no DTT-resistant conjugates (unpub-
lished data). At a high Chfr concentration (top), we detected
a series of ubiquitinated protein ladders, the fastest migrating
species having a mobility very close to that of the recombi-
nant Chfr, but different from that of E1 and Ubc4 (unpub-
lished data). We conclude that these radioactive bands repre-
sent covalent conjugates between Chfr and labeled ubiquitin,
and that Chfr acts as a ubiquitin ligase to auto-ubiquitinate
in the presence of E1 and Ubc4. Similarly, we detected for-
mation of Chfr–Ub conjugates with the Chfr protein ex-
pressed in 
 
Escherichia coli
 
 (unpublished data), thereby ex-
cluding the possibility that a contaminating protein from Sf9
cells may function as a ubiquitin ligase for Chfr.
At a high Chfr concentration (800 
 
 
 
g/ml; Fig. 1 C, top),
we detected a ladder of ubiquitinated Chfr. Interestingly, at
a lower Chfr concentration (20 
 
 
 
g/ml; Fig. 1 C, bottom),
the majority of ubiquitin conjugates formed had such high
molecular weights that they failed to enter the stacking gel.
Only a minor portion of the conjugates was trapped be-
tween the stacking gel and the separating gel. No mono- or
oligo-ubiquitin conjugates were detected. The different
modes of Chfr reactivity were likely due to the relative ratio
of Chfr to Ubc4 in these reactions, because the concentra-
tion of Ubc4 used in both panels was 10 
 
 
 
g/ml, a concen-
tration twofold higher than the molar concentration of Chfr
used in the bottom panel, but 20-fold lower than that of
Chfr in the top panel.
 
The ring finger domain in Chfr is required for 
its ligase activity
 
We next examined whether the ring finger domain is re-
quired for the ubiquitin ligase activity of the Chfr protein.
The domain structure of Chfr is illustrated in Fig. 2 A
(Scolnick and Halazonetis, 2000). We constructed three de-
letion mutants, ChfrF1–3, which consist of various regions
Figure 2. The ring finger domain is suffi-
cient to mediate the auto-ubiquitination 
reaction. (A) A schematic diagram for the 
domain structure of the Chfr protein and 
the deletion constructs used in this paper. 
(B) Chfr deletion mutants were expressed 
in E. coli and their expression levels were 
assayed by 12% SDS-PAGE. Lane 2, 
lysates of E.coli without Chfr mutant 
proteins. (C) Equal amounts of E. coli 
lysates expressing various recombinant 
proteins were incubated with radioactive 
ubiquitin in the presence of recombinant 
E1 and Ubc4 and the formation of 
ubiquitin conjugates was analyzed by 
reducing SDS-PAGE. (D) Purified ChfrF1 
(400  g/ml final concentration), ChfrF2 
(400  g/ml), and GST–ChfrF3 (200  g/ml) 
were incubated with radioactive 
ubiquitin in the presence of recombinant 
E1 and Ubc4 and the kinetics of ubiquitin 
conjugate formation was analyzed. 
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of the protein. All three fragments were expressed as soluble
proteins in 
 
E. coli
 
 (Fig. 2 B). When the lysates of 
 
E. coli
 
 ex-
pressing mutant proteins were incubated with radioactive
ubiquitin in the presence of E1 and Ubc4, we found that all
three fragments efficiently promoted auto-ubiquitination
(Fig. 2 C). Similarly, purified recombinant fragments also
ubiquitinated themselves (Fig. 2 D). The smallest construct
used in this experiment, glutathione-
 
S
 
-transferase (GST)–
ChfrF3, has less than 40 amino acids NH
 
2
 
-terminal to the
RF domain and less than 15 amino acids COOH-terminal
to the RF domain. We conclude that the RF domain and its
adjacent regions are sufficient for the auto-ubiquitination
activity of the Chfr protein. Interestingly, kinetic studies in-
dicate that the FHA domain at the NH
 
2
 
 terminus of the
protein actually reduces the ubiquitination activity of the
Chfr protein (Fig. 2 D, compare ChfrF1 with ChfrF2), sug-
gesting a potential role of the FHA domain in regulation of
the ligase activity.
To confirm the importance of the RF domain in the ligase
activity, we constructed two point mutations in the RF do-
main (Fig. 3 A). The mutated residues, Ile at amino acid 306
and Trp at amino acid 332, are well conserved within a sub-
group of RF domains that act as ubiquitin ligases (Fig. 3 A).
ChfrI306A and ChfrW332A were expressed in Sf9 cells and
purified to homogeneity. When analyzed for auto-ubiquiti-
nation activity, both mutants at a low protein concentration
(40 
 
 
 
g/ml) failed to auto-ubiquitinate, whereas the wild-
type Chfr protein efficiently auto-ubiquitinated (Fig. 3 B).
However, the mutant proteins did self-ubiquitinate at a
higher protein concentration (200 
 
 
 
g/ml), albeit at a still
lower efficiency than the wild-type protein.
We next examined whether these mutant proteins have
ubiquitin ligase activity in vivo
 
.
 
 Myc-tagged Chfr, ChfrI306A,
and ChfrW332A were transfected into HEK293T cells, and
all three proteins were expressed at the same level (Fig. 3 C).
Myc-tagged proteins were immunopurified by an anti-Myc
antibody and then assayed by Western blot analysis with an
anti-ubiquitin antibody. The wild-type Chfr immunopre-
cipitate, but not the mutant Chfr immunoprecipitates, con-
tained ubiquitinated protein(s) (Fig. 3 D). When the Myc–
Chfr immunoprecipitates were incubated with radioactive
ubiquitin in the presence of E1 and Ubc4, only the
wild-type Chfr complex efficiently promoted the formation
of ubiquitin conjugates (Fig. 3 E). Neither ChfrI306A nor
ChfrW332A were active under physiological conditions,
consistent with the biochemical analysis of their ligase activ-
ity using recombinant proteins. We conclude that the ubiq-
uitin ligase activity in the Chfr immunoprecipitate results
directly from the Chfr protein, and the RF domain in Chfr
is essential for the ligase activity in vivo.
 
The Chfr ligase acts with Ubc4 and Ubc5, but not with 
UbcH7 and UbcH10
 
We determined the specificity of the ubiquitin-conjugating
enzymes for the Chfr ligase. An immunofluorescence study
of the GFP–Chfr fusion protein indicated that Chfr is a nu-
clear protein (unpublished data). There are several ubiq-
uitin-conjugating enzymes that have been implicated in nu-
clear functions; these include Ubc4, Ubc5A, Ubc5B, and
UbcH10 (Jentsch et al., 1990; Hershko and Ciechanover,
1998). We tested whether these E2s act with Chfr in the
ubiquitination reaction. We also included UbcH7 as a nega-
tive control in our analysis, because UbcH7 is involved in
ubiquitinating ER-associated proteins.
Ubc4, Ubc5A, Ubc5B, UbcH10, and UbcH7 were ex-
pressed as recombinant proteins in 
 
E. coli
 
 and purified to
homogeneity (unpublished data). When incubated with re-
combinant E1 and radioactive ubiquitin, all these E2s
formed conjugates with ubiquitin that were only detectable
by nonreducing SDS-PAGE (Fig. 4 A), suggesting that these
conjugates were formed through thioester bonds. Thus, the
recombinant E2s analyzed here are all active.
We next examined whether various E2s can promote the
formation of Chfr–Ub conjugates. When incubated with re-
combinant Chfr and radioactive ubiquitin, only Ubc4,
Ubc5A, and Ubc5B, not UbcH10 and UbcH7, were active
Figure 3. The ring finger domain is required for 
the Chfr ligase activity. (A) Alignment of the ring 
finger domains from APC11, Chfr, and c-Cbl. (B) 
Purified recombinant Chfr, ChfrI306A, and 
ChfrW332A, at concentrations indicated, were 
incubated with radioactive ubiquitin in the 
presence of E1 and Ubc4, and the kinetics of 
ubiquitin conjugate formation was followed by
reducing SDS-PAGE. At the Chfr concentrations 
used here, all the ubiquitin conjugates stayed in 
the wells of the stacking gel and therefore only that 
portion of the gel is shown. (C–E) Myc–Chfr (lanes 
2), Myc–ChfrI306A (lanes 3), Myc–ChfrW332A 
(lanes 4), and control vector (lanes 1) were 
transfected into HEK293T cells and immuno-
precipitated by an anti-Myc antibody. The 
immunoprecipitates were analyzed by Western 
blotting with an anti-Myc antibody (C) or with an 
anti-ubiquitin antibody (D). In addition, immuno-
precipitates were incubated with radioactive 
ubiquitin in the presence of recombinant E1 and 
Ubc4 and assayed for ubiquitin ligase activity (E). 
Arrow in E points to the wells of the stacking gel. 
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in mediating the formation of Chfr–Ub conjugates (Fig. 4
B, top). In the same reactions, both UbcH10–Ub and
UbcH7–Ub conjugates accumulated to high levels, as as-
sayed by nonreducing SDS-PAGE (bottom), but ubiquitin
failed to transfer from E2 to Chfr.
 
Chfr inhibits the activation of MPF
 
Chfr delays entry into mitosis when the checkpoint pathway
is activated by mitotic stress, induced with taxol or nocoda-
zole (Scolnick and Halazonetis, 2000). We developed a cell-
free system to investigate how the Chfr pathway delays the
cell cycle progression.
Entry into mitosis can be monitored in 
 
Xenopus
 
 extracts
(Murray and Kirschner, 1989; Solomon et al., 1990). Addi-
tion of 
 
 
 
90 cyclin B, a mutant cyclin B with the first 90
amino acids truncated, to interphase extracts efficiently acti-
vated the Cdc2 kinase activity and drove extracts into mito-
sis (Fig. 5 A, top). However, the addition of wild-type Chfr
protein reduced the rate of Cdc2 activation and delayed en-
try into mitosis (Fig. 5, A and B). This inhibition of Cdc2
kinase activity required an active ligase, because the two in-
active mutants, ChfrI306A and ChfrW332A, both failed to
delay mitotic entry. Thus, Cdc2 is a key target for the Chfr
pathway to control the entry into mitosis.
We then examined whether the Chfr protein has any ef-
fect on cells already in mitosis. 
 
Xenopus
 
 mitotic extracts have
a high level of Cdc2 kinase activity, which is not affected by
the addition of wild-type Chfr or ChfrI306A protein to mi-
totic extracts (Fig. 5 C). Thus, the Chfr pathway only regu-
lates the initial activation of the Cdc2 kinase at the G2 to M
transition.
Chfr is a ubiquitin ligase and addition of an active ligase
to extracts could have a nonspecific effect on the entry into
 
mitosis if there is a specific requirement for ubiquitin-
dependent proteolysis in the G2 to M transition. For exam-
ple, active Chfr ligase may nonspecifically interfere with
physiological ubiquitin-dependent proteolysis by depleting
the ubiquitin pool or by competing for proteasome degrada-
tion in extracts. To establish whether there is a requirement
for ubiquitin-dependent proteolysis at the G2 to M tran-
sition, we examined the effect of methylated ubiquitin
(methyl-ubiquitin) and 
 
N
 
-acetyl-Leu-Leu-norleucinal peptide
(LLnL) on entry into mitosis. Methyl-ubiquitin interferes
with the formation of poly-ubiquitin conjugates required for
degradation and LLnL is an inhibitor of proteasomes. Nei-
ther methyl-ubiquitin nor LLnL delayed the mitotic entry,
as measured by the kinetics of activation of the Cdc2 kinase
(Fig. 6 A, left). The amount of methyl-ubiquitin and LLnL
used in these experiments, when added to mitotic extracts,
Figure 4. Chfr functions with Ubc4 and Ubc5, but not with 
UbcH7 and UbcH10. (A) A thioester assay for the activity of 
recombinant ubiquitin-conjugating enzymes. Recombinant E2s 
were incubated with E1 and then analyzed by nonreducing SDS-PAGE 
for E1 and E2s conjugated to ubiquitin through a thioester bond. 
Lane 1, E1 alone. (B) Purified recombinant Chfr (lanes 2–7) was 
incubated with radioactive ubiquitin in the presence of E1 and 
various E2s. The formation of the ubiquitin–Chfr conjugates was 
analyzed by reducing SDS-PAGE (top) and the formation of 
ubiquitin–E2s conjugates linked through a thioester bond was 
assayed by nonreducing SDS-PAGE (bottom). Under the reaction 
conditions, all the Chfr–Ub conjugates entered the separating gel. 
Arrow indicates the junction between the stacking and separating 
gels. Arrowhead points to an E1–Ub conjugate that is also present 
in control lanes (1 and 2). Lane 1, E1 alone. Lane 2, E1 and Chfr.
Figure 5. Chfr delays the activation of the Cdc2 kinase at the G2-M 
transition. (A and B) Xenopus interphase extracts were incubated 
with a buffer, Chfr, ChfrI306A, or ChfrW332A.  90 cyclin B was 
then added and the kinetics of the activation of the Cdc2 kinase was 
analyzed by measuring the phosphorylation of histone H1 with 
radioactive  -ATP. The Cdc2 kinase activity was quantitated and 
plotted against time (B). The unit for kinase activity is arbitrary. In 
five separate experiments, the wild-type Chfr protein always 
delayed the activation of Cdc2 kinase. The levels of the Cdc2 
activity at 60 min, from extracts treated with ChfrI306A and 
ChfrW332A, were slightly variable; in some experiments, these 
levels were close to, instead of higher than, that of the buffer 
control. (C) Xenopus mitotic extracts were incubated with a buffer, 
Chfr, or ChfrI306A, and the level of the Cdc2 kinase activity was 
analyzed using histone H1 as a substrate. 
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reduced the rate of cyclin degradation (Fig. 6 B), suggesting
that both methyl-ubiquitin and LLnL interfere with ubiq-
uitin-dependent proteolysis pathways in 
 
Xenopus
 
 extracts.
We conclude that there is no requirement for ubiquitin-
dependent proteolysis at the G2 to M transition under nor-
mal physiological conditions.
If Chfr ligase activity is required for the delay in mitotic
entry, inhibition of ubiquitination or degradation in extracts
should abolish the Chfr-dependent delay. This is indeed the
case, as addition of either methyl-ubiquitin or LLnL abol-
ished the Chfr-mediated delay before entry into mitosis (Fig.
6 A). We conclude that the Chfr-dependent checkpoint
controls entry into mitosis through ubiquitin-dependent
proteolysis.
 
Chfr prolongs the phosphorylated state of Tyr15 in 
Cdc2 at the G2 to M transition
 
We investigated how the Cdc2 kinase activity is regulated by
Chfr. When recombinant Chfr was incubated with inter-
phase extracts and 
 
 
 
90 cyclin B, the Chfr pathway delayed
the removal of inhibitory phosphorylation on Cdc2, as ana-
lyzed by an antibody specific to the tyrosine 15–phosphory-
lated Cdc2 (Fig. 7 A). 25 min after addition of 
 
 
 
90 cyclin
B, Cdc2 from both the control extracts and the Chfr-treated
extracts had significant levels of phosphorylated tyrosine. In-
terestingly, by 35 min, the level of phosphorylated tyrosine
was greatly reduced in control extracts, correlating well with
the activation of the Cdc2 kinase (Fig. 7 A). On the other
hand, the level of phosphorylated tyrosine in Chfr-treated
extracts remained very high, consistent with the observation
that the Cdc2 kinase was not activated until 45 min after the
addition of 
 
 
 
90 cyclin B (Fig. 7 A). We conclude that Chfr
delays mitotic entry by prolonging the phosphorylated state
of Cdc2.
At the G2 to M transition, Cdc2 is regulated by the Wee1
kinase through inhibitory phosphorylation at Thr14 and
Tyr15, and by the Cdc25C phosphatase through dephos-
phorylation (King et al., 1994). Wee1 and Cdc25C are reg-
ulated posttranslationally. Phosphorylation of Cdc25C acti-
vates its phosphatase activity, whereas phosphorylation of
Wee1 inactivates its kinase activity (Izumi et al., 1992;
Kumagai and Dunphy, 1992, 1996; Izumi and Maller,
1993). We found that Chfr delayed phosphorylation of both
Wee1 and Cdc25C at the G2 to M transition (Fig. 7 A). On
the other hand, Chfr had no effect on the steady-state level
of Cdc2, Wee1, and Cdc25C proteins, as extracts entered
mitosis (Fig. 7 A; and unpublished data), suggesting that not
one of these three proteins is the direct target for ubiquitina-
tion by Chfr. Similarly, the level of Chk1, a regulator of
Cdc25C at the G2 to M transition (Peng et al., 1997;
Sanchez et al., 1997), was not affected by Chfr (Fig. 7 A).
We conclude that the Chfr-mediated delay on the activation
of the Cdc2 kinase is due to a combination of over-activa-
Figure 6. Chfr-mediated inhibition of Cdc2 requires ubiquitin-
dependent protein degradation. (A) Xenopus interphase extracts 
were incubated with a buffer or Chfr in the presence or absence of 
methyl-ubiquitin and LLnL.  90 cyclin B was then added and the 
kinetics of the activation of the Cdc2 kinase was analyzed using 
histone H1 as a substrate. The exact kinetics of activation of Cdc2 in 
buffer control here are different from that in Fig. 5 due to variations 
between different extracts. (B) Methyl-ubiquitin and LLnL effectively 
inhibit ubiquitin-dependent proteolysis. Xenopus mitotic extracts 
were incubated with a buffer, methyl-ubiquitin, or LLnL. Radioactive 
cyclin B was then added and the kinetics of its degradation was 
analyzed by SDS-PAGE.
Figure 7. Chfr prolongs the phosphorylated state of Tyr15 in 
Cdc2 at the G2-M transition. (A) Xenopus interphase extracts were 
incubated with a buffer or Chfr.  90 cyclin B was then added and 
the activation of the Cdc2 kinase was analyzed by measuring the 
phosphorylation of histone H1. The kinetics of entry into mitosis 
was also measured by the level and the phosphorylation state of 
Cdc2, Cdc25C, Wee1, and Chk1 in Western blot analysis. Arrow-
heads point to nonspecific, cross-reacting bands. (B) Xenopus 
cycling extracts were incubated with a buffer or Chfr and the kinetics 
of entry into mitosis was measured by the Cdc2 kinase activity and 
by the phosphorylation state of Cdc25C and Wee1. Arrowheads 
point to nonspecific, cross-reacting bands. 
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tion of the inhibitory kinase Wee1 and an inhibition of the
Cdc25C phosphatase.
We observed a more pronounced delay of mitotic entry in
 
Xenopus
 
 cycling extracts. Control extracts entered mitosis
twice in the first 2 h, first at 70 min and then at 120 min, as
analyzed by the activity of the Cdc2 kinase and the phos-
phorylation states of Cdc25C and Wee1 (Fig. 7 B). How-
ever, the entry into mitosis in Chfr-treated extracts was de-
layed by more than one cell cycle; such extracts did not enter
mitosis until 130 min. This delay for the G2 to M transition
correlates well with the delayed phosphorylation of Cdc25C
and Wee1 (Fig. 7 B). It is likely that the shorter delay ob-
served in extracts treated with 
 
 
 
90 cyclin B reflects the high
concentration of 
 
 
 
90 cyclin B used in these experiments,
and that cycling extracts more closely reflect the physiologi-
cal process in vivo.
 
Chfr ubiquitinates Polo-like kinase 1 (Plk1)
 
To identify the substrate of the Chfr ligases, we analyzed the
ability of Chfr to ubiquitinate regulators of Cdc2 in 
 
Xenopus
 
extracts. The addition of recombinant Chfr to interphase ex-
tracts did not change the stability of in vitro translated
Cdc25C and Wee1 (Fig. 8 A), consistent with the Western
blot analysis of the endogenous Cdc25C and Wee1 (Fig. 7).
Thus, neither Cdc25C nor Wee1 is the substrate of Chfr.
We next tested the stability of Plk1, a positive regulator for
Cdc25C and a negative regulator for Wee1 at the G2 to M
transition (King et al., 1994). When incubated with inter-
phase extracts, in vitro–translated Plk1 was efficiently ubiq-
uitinated in a Chfr-dependent manner (Fig. 8 A). Indeed,
Plk1 is a substrate of Chfr. In an in vitro reconstituted reac-
tion, Plk1, but not Cdc25C and Wee1, was quantitatively
ubiquitinated in the presence of purified recombinant E1,
Ubc4, and Chfr (Fig. 8 B).
The endogenous Plx1, the 
 
Xenopus
 
 homologue of human
Plk1, was also modified in a Chfr-dependent manner (Fig.
8, C and D). When incubated with 
 
 
 
90 cyclin B, Chfr de-
layed entry into mitosis. This delay correlates with the gen-
eration of a ladder of Plx1 bands migrating slower than the
unmodified Plx1, as analyzed by an anti-Plx1 blotting (Fig.
8 C). To confirm that these slow-migrating bands repre-
sented ubiquitinated Plx1, interphase extracts were incu-
bated with GST–Ub in the presence or absence of recombi-
nant Chfr. After various incubation times, two sets of
aliquots were collected, one for Western blot analysis by the
anti-Plx1 antibody, and the other for purification of GST–
Ub conjugates using glutathione agarose beads (Fig. 8 D).
Purified conjugates were then analyzed by Western blotting
using the anti-Plx1 antibody to detect ubiquitinated Plx1. In
the absence of Chfr, Plx1 migrated as a single band and
therefore was not ubiquitinated in interphase extracts. Addi-
tion of Chfr promoted the formation of high molecular
weight forms of Plx1, which were covalently linked to GST–
Ub (Fig. 8 D). Thus, endogenous Plx1 is ubiquitinated by
Chfr.
The extent of ubiquitination of endogenous Plx1 is lim-
ited in interphase extracts. We noticed that 
 
Xenopus
 
 extracts
had a limited capacity for ubiquitination and that efficient
ubiquitination of cell cycle regulators required exogenously
added recombinant ubiquitin protein. For example, com-
Figure 8. Plk1 is the substrate of Chfr ligase. (A) In vitro–translated 
Cdc25, Wee1, and Plk1 were incubated with Xenopus interphase 
extracts and ubiquitin, either in the presence or absence of recombi-
nant Chfr, and the ubiquitination of these proteins was analyzed by 
SDS-PAGE. (B) In vitro–translated Cdc25, Wee1, and Plk1 were 
incubated with recombinant E1, E2, ubiquitin, and ATP, either in the 
presence or absence of recombinant Chfr, and the ubiquitination of 
these proteins was analyzed by SDS-PAGE. (C) Xenopus interphase 
extracts were incubated with a buffer or Chfr.  90 cyclin B was then 
added and the kinetics of the activation of the Cdc2 kinase was ana-
lyzed by measuring the phosphorylation of histone H1. Duplicated 
samples were analyzed in Western blot with an antibody against 
Xenopus Plx1. Arrowheads point to nonspecific, cross-reacting bands. 
(D) Xenopus interphase extracts were incubated with GST–Ub plus 
a buffer or Chfr. Samples were collected at various time points to 
directly blot against an anti-Plx1 antibody. In addition, GST–Ub 
conjugates were purified with glutathione beads and then assayed by 
Western blot analysis using the anti-Plx1 antibody. Arrowheads point 
to nonspecific, cross-reacting bands. (E) Xenopus interphase extracts 
were incubated with recombinant ubiquitin (at 2 mg/ml) plus a buffer 
or Chfr for 5 min.  90 cyclin B was then added and the kinetics of 
entry into mitosis was measured by the Cdc2 kinase activity and by 
the phosphorylation state of Cdc2, Cdc25C, and Wee1. The degree of 
ubiquitination of Plx1 was assayed by Western blotting with an anti-
Plx1 antibody. Arrowheads point to nonspecific, cross-reacting bands. 
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plete degradation of mitotic cyclin B by the APC pathway
requires the addition of ubiquitin to mitotic extracts (Fang
et al., 1998a,b). In the presence of recombinant ubiquitin,
endogenous Plx1 was quantitatively ubiquitinated by Chfr
and subsequently degraded by proteasomes (Fig. 8 E). Com-
plete ubiquitination and degradation of Plx1 prevented the
phosphorylation of Cdc25C and Wee1 in Chfr-treated ex-
tracts, such that Cdc2 remained phosphorylated and its ki-
nase activity was not activated, even after extended incuba-
tion with 
 
 
 
90 cyclin B (Fig. 8 E). In the presence of Chfr,
even the residual level of Cdc2 kinase activity detectable in
interphase extracts was downregulated. We conclude that
Chfr ubiquitinates and downregulates Plx1, which, in turn,
simultaneously regulates Cdc25C and Wee1 activities, lead-
ing to prolonged phosphorylation of Cdc2 and a delay in
entry into mitosis.
 
Discussion
 
Chfr is a checkpoint protein required for a delay in entry
into mitosis in response to mitotic stress (Scolnick and Hala-
zonetis, 2000). We show here that Chfr is a ubiquitin ligase
that regulates the activation of the Cdc2 kinase at the G2 to
M transition. Chfr targets Plk1 for ubiquitination and deg-
radation, leading to the downregulation of Cdc25C phos-
phatase activity and upregulation of Wee1 kinase activity.
Thus, Chfr defines a novel ubiquitin-dependent proteolysis
pathway that controls entry into mitosis.
 
The checkpoint protein Chfr is a ubiquitin ligase
 
Chfr is a ubiquitin ligase based on the following observations.
First, the Chfr protein has a ring finger domain common to a
growing number of ubiquitin ligases (Jackson et al., 2000;
Joazeiro and Weissman, 2000; Scolnick and Halazonetis,
2000). Sequence alignment of the Chfr ring finger domain
with those from APC11 and c-Cbl indicates that they are
highly homologous. The cocrystal structure of c-Cbl and
UbcH7 have been solved recently and the ring finger domain
in c-Cbl has been shown to directly bind to UbcH7 (Zheng et
al., 2000), indicating an important role of the ring finger do-
main in the ubiquitin ligase activity. Residues in c-Cbl in-
volved in interacting with UbcH7 are partly conserved in Chfr;
these residues include Ile306, Cys328, Trp332, and Pro340
(amino acid numbers derived from the Chfr protein). Second,
recombinant Chfr auto-ubiquitinates in an E1- and E2-depen-
dent manner. Auto-ubiquitination is a hallmark of ring finger–
containing ligases (Joazeiro et al., 1999; Huang et al., 2000;
Suzuki et al., 2001). Indeed, both c-Cbl and APC11 have
auto-ubiquitination activities in the absence of substrates
(Joazeiro et al., 1999; Gmachl et al., 2000; Leverson et al.,
2000). We showed here that the ring finger domain in Chfr is
both necessary and sufficient for the auto-ubiquitination activ-
ity. Third, when expressed in mammalian tissue culture cells,
the Chfr immunoprecipitate also contains a ubiquitinated pro-
tein(s) and promotes the formation of high molecular weight
ubiquitin conjugates, indicating that the Chfr immunoprecipi-
tate has a ubiquitin ligase activity. Again, the ring finger do-
main in Chfr is essential for the ligase activity in vivo, because
point mutations of conserved residues in this domain abolish
the ubiquitin ligase activity. Fourth, Plk1 is ubiquitinated in
 
Xenopus
 
 extracts in a Chfr-dependent manner, and in a puri-
fied, reconstituted system, Chfr directly ubiquitinates Plk1.
Thus, Chfr by itself is sufficient to ubiquitinate the substrate.
How is the ligase activity toward itself and the substrates
differentially regulated? There are at least two possible
mechanisms for this regulation. First, the auto-ubiquitina-
tion activity may be separable from the ligase activity toward
substrates, with self-ubiquitination and ubiquitination of
substrates being mutually exclusive. An example of a ligase
with such a mechanism is the MDM2 protein, a ring finger–
containing ligase for the tumor suppressor p53. MDM2
ubiquitinates itself as well as p53 (Fang et al., 2000). The li-
gase is modified in the ring finger domain by SUMO-1, a
ubiquitin-like protein. Modification by SUMO-1 prevents
self-ubiquitination and increases its ligase activity toward
p53 (Buschmann et al., 2000). On the other hand, a reduc-
tion of the SUMO-1 modification destabilizes MDM2 and
increases the level of p53. A second possibility is that Chfr
may ubiquitinate itself and its substrates at the same time,
and ubiquitinated Chfr and substrates are degraded by pro-
teasomes. Such a mechanism exists for the c-Cbl ligase. C-Cbl
mediates the ubiquitination of itself and c-Src. Ubiquitina-
tion of both proteins requires Src kinase activity and tyrosine
phosphorylation of c-Cbl by Src (Yokouchi et al., 2001),
suggesting that substrate ubiquitination and auto-ubiquiti-
nation are interdependent. The 
 
Xenopus
 
 extract system should
allow us to determine the regulatory mechanism of Chfr
self-ubiquitination versus ubiquitination of Plk1.
 
Chfr delays entry into mitosis by inhibiting the 
activation of Cdc2
 
The Chfr-mediated checkpoint controls entry into mitosis
(Scolnick and Halazonetis, 2000). Normal primary cells and
tumor cell lines with wild-type Chfr exhibit a delay in entry
into mitosis when centrosome separation is inhibited by no-
codazole or taxol. On the other hand, tumor cell lines that
lack the functional Chfr protein enter mitosis without such a
delay in the presence of mitotic stress. Importantly, ectopic
expression of Chfr in tumor cell lines restores the delay, in-
dicating that the Chfr protein is responsible for the delay in
entry into mitosis. Similarly, ectopic expression of the active
Chfr protein in 
 
Xenopus
 
 extracts is likely to mimic a check-
point-activated state, and our cell-free system allows us to
investigate the molecular pathway that Chfr regulates. It is
interesting to note that the Chfr-minus cells seem to have a
normal G2 to M transition in the absence of mitotic stress
(Scolnick and Halazonetis, 2000). Thus, the Chfr protein is
only required for a checkpoint mechanism that controls the
kinetics of mitotic entry in the presence of mitotic stress.
This is consistent with our observation that there is no re-
quirement for ubiquitin-dependent proteolysis at the nor-
mal G2 to M transition. Although we have not examined
the function of endogenous Chfr protein in 
 
Xenopus
 
 extracts
due to the lack of a high-quality anti-Chfr antibody for im-
munodepletion experiments, the endogenous Chfr, if ex-
pressed in 
 
Xenopus
 
 embryonic extracts, is unlikely to be re-
quired for entry into mitosis in the absence of the
checkpoint signal. 
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When added to 
 
Xenopus
 
 extracts, the Chfr ligase delays
entry into mitosis with a prolonged phosphorylation of tyro-
sine 15 in the Cdc2 kinase. In cycling extracts, the Chfr pro-
tein delays the activation of Cdc2 by more than one cell cy-
cle. Given that the inactive Chfr mutants have no effect on
mitotic entry, and the inhibition of ubiquitin-dependent
protein degradation rescues the delay phenotype, the effect
of Chfr on mitotic entry is specific and requires ubiquitin-
dependent protein degradation.
It is interesting to note that in mammalian tissue culture
cells, the Chfr pathway causes a delay in entry into mitosis
without a detectable delay in the activation of the Cdc2 ki-
nase (Scolnick and Halazonetis, 2000). It is possible that the
temporal delay in activation of Cdc2 kinase found in 
 
Xenopus
 
extracts could have escaped from detection in the mammalian
system due to a large time interval (2 h) between time points
used in the original analysis of the Cdc2 kinase activity. This
discrepancy between 
 
Xenopus
 
 extracts and mammalian tissue
culture cells may also result from difficulties in achieving an
optimal synchronization in mammalian cells (Scolnick and
Halazonetis, 2000). In addition, we found that constitutive
expression of Chfr in mammalian cells is detrimental to cell
proliferation and the expression level of the exogenously in-
troduced Chfr was quickly diminished in stable Chfr cell
lines (unpublished data). On the other hand, it has been re-
ported that the Chfr checkpoint temporarily arrests mamma-
lian cells at prophase with an intact nuclear envelope and un-
condensed chromosomes (Scolnick and Halazonetis, 2000),
consistent with a low level of the Cdc2 kinase activity.
 
Plk1 is ubiquitinated by Chfr
 
The direct target of the Chfr pathway is Plk1. In vitro–trans-
lated Plk1 is ubiquitinated, in a Chfr-dependent manner,
both in 
 
Xenopus
 
 interphase extracts as well as in a purified
system reconstituted with recombinant proteins. On the
other hand, neither Cdc25C nor Wee1 is ubiquitinated in
both assays, demonstrating the specificity of the Chfr path-
way. The endogenous Plx1 is also ubiquitinated in Chfr-
treated 
 
Xenopus
 
 extracts, and this ubiquitination correlates
with the delay in entry into mitosis. Indeed, if the efficiency
of the Chfr pathway is augmented by recombinant ubiq-
uitin, endogenous Plx1 is quantitatively ubiquitinated and
the Chfr-treated extracts are arrested at G2 with minimal
Cdc2 kinase activity. We expect that 
 
Xenopus
 
 extracts reflect
certain aspects of Plk1 regulation in mammalian somatic
cells. The expression of Plk1 is regulated in mammalian
cells; Plk1 begins to accumulate in G2 and its level peaks in
mitosis (Fang et al., 1998a). Activation of the Chfr pathway
by mitotic stress leads to ubiquitination and degradation of
Plk1, and blocks entry into mitosis. Once mitotic stress is re-
lieved and defects are repaired, the Chfr ligase is inactivated
and de novo synthesis of Plk1 drives cells into mitosis.
Plk1 regulates both the Wee1 kinase and the Cdc25C
phosphatase, which in turn control the Cdc2 kinase activity
at the G2 to M transition (Russell and Nurse, 1986; Gould
and Nurse, 1989; Ferrell et al., 1991; Gautier et al., 1991;
Kumagai and Dunphy, 1991; Osmani et al., 1991; Kumagai
and Dunphy, 1992). Wee1 mediates the inhibitory phos-
phorylation of Tyr15 and Thr14 on Cdc2, whereas Cdc25C
dephosphorylates and activates Cdc2. Cdc25C and Wee1
 
themselves are regulated by complex molecular circuits in
the cell cycle (King et al., 1994). The NH
 
2
 
-terminal regula-
tory domain in Cdc25C is phosphorylated by Plk1 and
Cdc2/cyclin B, and phosphorylation enhances the phos-
phatase activity of Cdc25C (Izumi et al., 1992; Kumagai
and Dunphy, 1992; Izumi and Maller, 1993; Kumagai and
Dunphy, 1996). On the other hand, Wee1 is also likely to
be phosphorylated by Plk1 and Cdc2/cyclin B, but phos-
phorylation inhibits the kinase activity of Wee1. Thus, the
activation of Cdc25C and Cdc2 and the inhibition of Wee1
at mitosis constitute an auto-activating feedback loop that
allows the Cdc2 kinase to be activated in an all-or-none
fashion (King et al., 1994). The initial activity of Plk1 at the
G2 to M transition can determine the status of the auto-acti-
vating loop and the level of the Cdc2 kinase activity.
We reported here that Plk1 is a target for the Chfr-medi-
ated checkpoint control. Plk1 is a kinase initially identified
for its role in controlling the separation of duplicated cen-
trosomes at the G2 to M transition (Llamazares et al.,
1991; Lane and Nigg, 1996). Thus, the Chfr pathway may
also delay the separation of centrosomes in the presence of
microtubule drugs, thereby providing additional time for
repairing defects in the centrosome structure. We speculate
that the Chfr checkpoint may control multiple steps at the
G2 to M transition. Indeed, in the two other ubiquitina-
tion pathways, SCF ligase and APC ligase, each has multi-
ple substrates and controls several events in the cell cycle
(Fang et al., 1999; Jackson et al., 2000). The demonstra-
tion of Chfr as a ubiquitin ligase and the identification of
Plk1 and Cdc2 as targets for the Chfr pathway will allow
us to begin to understand the biological function of this
novel ubiquitination pathway.
 
Materials and methods
 
Antibodies
 
Rabbit and mouse anti-Myc antibodies, anti-ubiquitin antibody, and anti-
Cdc2 antibody were purchased from Santa Cruz Biotechnology Inc., and
were used at 0.1 
 
 
 
g/ml for immunoprecipitation and at 1 
 
 
 
g/ml for West-
ern blot analysis. Rabbit antibody against Tyr15-phosphorylated Cdc2 was
purchased from Cell Signaling, Inc., and the mouse anti-Plx1 antibody was
from Zymed Laboratories. Antibodies against 
 
Xenopus
 
 cyclin A, Wee1,
and Cdc25C were gifts from Drs. Tod Stukenberg (University of Virginia,
Charlottesville, VA), Bill Dunphy (California Institute of Technology, Pasa-
dena, CA), Jim Ferrell (Stanford University, Palo Alto, CA), and James
Maller (University of Colorado, Denver, CO).
 
Expression and purification of recombinant proteins
 
Human Chfr gene was subcloned by PCR amplification into pFastBac
(GIBCO BRL), expressed as a soluble protein in Sf9 cells, and purified to
homogeneity. ChfrI306A and ChfrW332A mutants were constructed with
the Quick Change Site-Directed Mutagenesis Kit (Stratagene), and mutant
proteins were expressed and purified. Deletion mutants of Chfr were con-
structed by PCR amplification and mutant proteins were expressed in
 
E. coli
 
. ChfrF1 and ChfrF2 were purified by Ni-NTA beads (QIAGEN), and
GST–ChfrF3 was purified by glutathione-agarose beads (Amersham Phar-
macia Biotech). Human Ubc5A, Ubc5B, and UbcH7 genes were cloned
into a modified pET28a vector by PCR amplification from human fetal thy-
mus cDNA. Recombinant proteins were expressed in 
 
E. coli
 
 and purified
by Ni-NTA beads. Expression and purification of recombinant E1, Ubc4,
and UbcH10 were described previously (Fang et al., 1998a,b).
 
Ubiquitination Assays
 
Ubiquitin (Sigma-Aldrich) was labeled with 
 
125
 
I to a specific activity of 100
 
 
 
Ci/
 
 
 
g using the chloramine T procedure. For auto-ubiquitination of re-
combinant Chfr in Figs. 1–3, reactions were performed in a total volume of 
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l. The reaction mixture contained an energy-regenerating system, 400
 
 
 
g/ml labeled ubiquitin, 20 
 
 
 
g/ml recombinant E1, 10 
 
 
 
g/ml Ubc4, and
various amounts of Chfr as indicated in figure legends. Reactions were in-
cubated at room temperature for various times, quenched with SDS sam-
ple buffer, and analyzed by reducing 12% SDS-PAGE. Gels were scanned
with a PhosphorImager (Molecular Dynamics).
For ubiquitination assays with Myc–Chfr complexes from HEK293T
cells (Figs. 1 and 3), anti-Myc immunoprecipitates were purified from one
jumbo dish of transfected HEK293T cells and incubated with 400 
 
 
 
g/ml la-
beled ubiquitin, 20 
 
 
 
g/ml recombinant E1, 300 
 
 
 
g/ml Ubc4, and an en-
ergy-regenerating system at room temperature for 1 h. The reactions were
quenched with SDS sample buffer and analyzed by reducing 10% SDS-
PAGE.
For auto-ubiquitination assays with various E2s in Fig. 4 B, Chfr at 400
 
 
 
g/ml were incubated at room temperature for 5 min with 30 
 
 
 
g/ml la-
beled ubiquitin, 200 
 
 
 
g/ml recombinant E1, 200 
 
 
 
g/ml various E2s, and
an energy-regenerating system. The reactions were quenched with SDS
sample buffer and analyzed by reducing 10% SDS-PAGE.
For ubiquitination of Plk1, recombinant Chfr was incubated at room
temperature for various times with in vitro–translated [
 
35
 
S]Plk1 in the pres-
ence of E1, Ubc4, ubiquitin, and ubiquitin aldehyde, quenched with SDS
sample buffer, and analyzed by SDS-PAGE. To confirm that the endoge-
nous Plx1 is ubiquitinated in a Chfr-dependent manner, immobilized GST–
Ub was incubated with 
 
Xenopus
 
 interphase extracts in the presence or ab-
sence of recombinant Chfr protein. The final concentration of GST–Ub in
extracts was 0.85 mg/ml. Ubiquitinated products were purified by glu-
tathione beads and immunoblotted with an anti-Plx1 antibody.
The thioester assay for E2, histone H1 kinase assay, and cyclin degrada-
tion assay were performed as described previously (Fang et al., 1998a,b).
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